M Sacco, F Pellegrini, MC Roncaglioni, F … - Diabetes Care, 2003 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—The Primary Prevention Project (PPP) is a
randomized, open trial with a two-by-two factorial design aimed to investigate
low-dose aspirin (100 mg/day) and vitamin E (300 mg/day) in the prevention ... Cited by 97 - Related articles - All 4 versions
- Free from Publisher A Nicolucci - Diabetes Care, 2003 - 万方数据资源系统 OBJECTIVE:-We investigated in general practice the efficacy of antiplatelets and
antioxidants in primary prevention of cardiovascular events in people with type
2 diabetes. RESEARCH DESIGN AND METHODS-The Primary Prevention Project ... Cited by 135 - Related articles - BL Direct - All 4 versions
C Watala, J Golanski, J Pluta, M Boncler, M … - Thrombosis research, 2004 - Elsevier Aspirin (acetylsalicylic acid, ASA), which is recommended for primary and
secondary prevention in diabetes mellitus (DM), has been shown to have a lower
antiplatelet activity in diabetic patients. We conducted a crossover ... Cited by 87 - Related articles - All 8 versions
C Watala, J Pluta, J Golanski, M Rozalski, M … - Journal of Molecular Medicine, 2005 - Springer Page 1. J Mol Med (2005) 83:148–158 DOI 10.1007/s00109-004-0600-x ORIGINAL
ARTICLE Cezary Watala · Justyna Pluta · Jacek Golanski ... Cited by 48 - Related articles - All 4 versions
SS Mehta, RJ Silver, A Aaronson, M … - The American journal of cardiology, 2006 - Elsevier This study sought to determine the frequency of aspirin resistance in an
ambulatory population of patients with type 1 diabetes mellitus (T1D) or type 2
diabetes mellitus (T2D). Platelet aggregation was assessed during the ... Cited by 32 - Related articles - All 11 versions
V Evangelista, L Totani, S Rotondo, R … - Thrombosis and haemostasis, 2005 - ncbi.nlm.nih.gov Atherosclerotic cardiovascular disease and its thrombotic complications are the
principal causes of morbidity and mortality in patients with type-2 diabetes.
Aspirin reduces the risk of thrombotic events in a broad range of patients ... Cited by 38 - Related articles - All 4 versions
A Agustí, E Diogène - Med Clin (Barc), 2004 - icf.uab.es Respuesta El beneficio del tratamiento con AAS para prevenir la apari- ción de
un nuevo acontecimiento cardiovascular en los pa- cientes que ya han presentado
uno antes está bien estable- cido1,2. Sin embargo, su uso en los pacientes ... Cited by 4 - Related articles - BL Direct - All 7 versions
- ►highwire.org M Friend, I Vucenik, M Miller - Bmj, 2003 - bmjcom.highwire.org Aspirin 325 mg/day reduces the rate of events associated with coronary heart
disease. In most people, aspirin produces irreversible inhibition of platelet
aggregation, but in a sizeable minority of patients, the degree of platelet ... Cited by 122 - Related articles - BL Direct - All 11 versions
S Fateh-Moghadam, U Plöckinger, N Cabeza, … - Acta Diabetologica, 2005 - Springer Cardiovascular complications are still the leading cause of death among patients
with type 2 diabetes, accounting for 70% of all case fatalities [1, 2]. Numerous
patho- physiological mechanisms have been proposed to explain the ... Cited by 45 - Related articles - All 3 versions
- ►hematologylibrary.org [PDF] G DiMinno, MJ Silver, AM Cerbone, S Murphy - Blood, 1986 - bloodjournal.hematologylibrary.org . Hematology; all rights reserved Copyright 2007 by The American Society of DC
20036. by the American Society of Hematology, 1900 M St, NW, Suite 200,
Washington Blood (print ISSN 0006-4971, online ISSN 1528-0020), is ... Cited by 48 - Related articles - All 5 versions
